Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBDISC study of lenograstim as adjunct to anti-TNF therapy in inflammatory bowel disease
2008-008285-12Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenograstim in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Policlinico Gemelli. Primary endpoints: Feasibility and Tolerability. Started Apr 2009; status: completed.
02
Drugs
lenograstim
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2008-008285-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008285-12.